COYA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.33 USD | -2.27% |
|
-7.33% | -1.08% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 12.27 | 106.7 | 113.4 | - |
| Enterprise Value (EV) 1 | 12.27 | 106.7 | 113.4 | 113.4 |
| P/E ratio | -1 x | -9.38 x | -6.31 x | -4.85 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 17.8 x | 22.2 x | 16.8 x |
| EV / Revenue | - | 17.8 x | 22.2 x | 16.8 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 2,590 | 14,401 | 15,221 | - |
| Reference price 2 | 4.738 | 7.410 | 7.450 | 7.450 |
| Announcement Date | 29/03/23 | 19/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 6 | 5.114 | 6.75 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -9.812 | -7.903 | -16.97 | -28.26 |
| Operating Margin | - | - | -131.72% | -331.81% | -418.7% |
| Earnings before Tax (EBT) 1 | - | -12.24 | -7.264 | -16.22 | -28.04 |
| Net income 1 | -4.892 | -12.24 | -7.988 | -16.22 | -28.04 |
| Net margin | - | - | -133.13% | -317.3% | -415.42% |
| EPS 2 | -0.3300 | -4.730 | -0.7900 | -1.180 | -1.535 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 18/11/22 | 29/03/23 | 19/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 6 | - | 4.2 | 4.2 | - | 0.9 | 0.9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.9 | -2.904 | -3.564 | 1.815 | - | -1.778 | -2.428 | -7.278 | - | - |
| Operating Margin | - | - | - | 30.25% | - | -42.33% | -57.81% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.095 | -3.422 | 1.99 | - | -1.67 | -2.324 | -7.179 | - | - |
| Net income 1 | -2.736 | -3.095 | -3.422 | 1.266 | -5.052 | -1.67 | -2.324 | -7.179 | -8.1 | 0.95 |
| Net margin | - | - | - | 21.1% | - | -39.76% | -55.33% | - | -900% | 105.56% |
| EPS 2 | -0.2800 | -0.3100 | -0.3400 | 0.1500 | -0.3500 | -0.1100 | -0.1600 | -0.4900 | -0.4450 | -0.1350 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/05/23 | 08/08/23 | 08/11/23 | 19/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 18/11/22 | 29/03/23 | 19/03/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.5
USD
Average target price
14.5
USD
Spread / Average Target
+93.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.08% | 114M | |
| +46.19% | 56.65B | |
| -6.14% | 39.44B | |
| +39.19% | 39.03B | |
| -6.65% | 26.86B | |
| +12.33% | 26.75B | |
| -21.78% | 19.03B | |
| -0.35% | 12.28B | |
| +24.18% | 12.26B | |
| +28.38% | 12.04B |
- Stock Market
- Equities
- COYA Stock
- Financials Coya Therapeutics, Inc.
